Neda Rasouli
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 38 | 2024 | 1241 | 4.160 |
Why?
| | Diabetes Mellitus, Type 2 | 43 | 2026 | 2583 | 4.070 |
Why?
| | Metformin | 21 | 2026 | 318 | 2.890 |
Why?
| | Thiazolidinediones | 20 | 2014 | 138 | 2.260 |
Why?
| | Prediabetic State | 10 | 2024 | 245 | 2.200 |
Why?
| | Hypoglycemic Agents | 36 | 2026 | 1387 | 2.140 |
Why?
| | Adipose Tissue | 24 | 2016 | 652 | 1.960 |
Why?
| | Insulin-Secreting Cells | 8 | 2025 | 388 | 1.900 |
Why?
| | Sulfonylurea Compounds | 7 | 2026 | 51 | 1.420 |
Why?
| | Blood Glucose | 28 | 2026 | 2327 | 1.360 |
Why?
| | Vitamin D Deficiency | 2 | 2022 | 186 | 1.240 |
Why?
| | Glucagon-Like Peptides | 3 | 2025 | 70 | 1.230 |
Why?
| | Obesity | 24 | 2019 | 3077 | 1.170 |
Why?
| | Cholecalciferol | 4 | 2022 | 60 | 1.140 |
Why?
| | Insulin | 24 | 2026 | 2507 | 1.110 |
Why?
| | Insulin Glargine | 11 | 2026 | 88 | 1.070 |
Why?
| | Peripheral Arterial Disease | 4 | 2025 | 503 | 0.980 |
Why?
| | Cholesterol, HDL | 2 | 2018 | 200 | 0.950 |
Why?
| | Triglycerides | 3 | 2018 | 520 | 0.870 |
Why?
| | Fenofibrate | 2 | 2016 | 28 | 0.850 |
Why?
| | Glucose Tolerance Test | 15 | 2025 | 361 | 0.820 |
Why?
| | Muscle, Skeletal | 11 | 2016 | 1795 | 0.710 |
Why?
| | Metabolic Syndrome | 3 | 2018 | 354 | 0.680 |
Why?
| | Diabetes Mellitus | 7 | 2025 | 1098 | 0.670 |
Why?
| | Receptors, Ghrelin | 1 | 2020 | 7 | 0.660 |
Why?
| | Gastroparesis | 1 | 2020 | 9 | 0.650 |
Why?
| | PPAR gamma | 8 | 2014 | 176 | 0.650 |
Why?
| | Middle Aged | 55 | 2026 | 35875 | 0.620 |
Why?
| | Lipid Metabolism | 5 | 2016 | 527 | 0.620 |
Why?
| | Vitamin D | 9 | 2024 | 400 | 0.600 |
Why?
| | C-Peptide | 4 | 2026 | 189 | 0.600 |
Why?
| | Diabetic Neuropathies | 1 | 2020 | 99 | 0.600 |
Why?
| | Glucose | 9 | 2024 | 1047 | 0.590 |
Why?
| | Adipokines | 2 | 2010 | 57 | 0.590 |
Why?
| | Subcutaneous Fat | 5 | 2014 | 78 | 0.560 |
Why?
| | Hypoxia | 2 | 2016 | 1199 | 0.550 |
Why?
| | Adipocytes | 11 | 2014 | 223 | 0.540 |
Why?
| | Sitagliptin Phosphate | 7 | 2026 | 31 | 0.510 |
Why?
| | Humans | 90 | 2026 | 144759 | 0.510 |
Why?
| | Liraglutide | 7 | 2026 | 32 | 0.510 |
Why?
| | Dietary Supplements | 7 | 2022 | 576 | 0.490 |
Why?
| | Hyperglycemia | 5 | 2016 | 375 | 0.480 |
Why?
| | Aged | 33 | 2026 | 25913 | 0.480 |
Why?
| | Vitamins | 6 | 2024 | 178 | 0.470 |
Why?
| | Remote Consultation | 1 | 2016 | 66 | 0.450 |
Why?
| | Fibrosis | 3 | 2023 | 548 | 0.450 |
Why?
| | Fatty Acids | 2 | 2016 | 450 | 0.440 |
Why?
| | Macrophages | 10 | 2014 | 1511 | 0.430 |
Why?
| | Female | 52 | 2026 | 78271 | 0.420 |
Why?
| | Male | 51 | 2026 | 72315 | 0.420 |
Why?
| | Adult | 46 | 2026 | 40449 | 0.410 |
Why?
| | Inflammation | 12 | 2016 | 2878 | 0.410 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 14 | 0.370 |
Why?
| | SUMO-1 Protein | 1 | 2012 | 22 | 0.370 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 146 | 0.360 |
Why?
| | Walking | 3 | 2025 | 545 | 0.360 |
Why?
| | Double-Blind Method | 7 | 2025 | 2029 | 0.350 |
Why?
| | Glucose Intolerance | 6 | 2010 | 142 | 0.350 |
Why?
| | Histone Deacetylases | 1 | 2012 | 210 | 0.320 |
Why?
| | Patient Admission | 1 | 2012 | 218 | 0.320 |
Why?
| | Cohort Studies | 7 | 2020 | 5960 | 0.310 |
Why?
| | Lipids | 2 | 2020 | 710 | 0.310 |
Why?
| | Receptors, Scavenger | 1 | 2009 | 22 | 0.300 |
Why?
| | Gene Expression Regulation | 6 | 2015 | 2608 | 0.290 |
Why?
| | Inpatients | 2 | 2013 | 545 | 0.290 |
Why?
| | Gene Expression | 7 | 2010 | 1490 | 0.270 |
Why?
| | Metabolic Diseases | 1 | 2008 | 114 | 0.260 |
Why?
| | Body Mass Index | 11 | 2021 | 2438 | 0.260 |
Why?
| | Intermittent Claudication | 2 | 2025 | 121 | 0.250 |
Why?
| | Choristoma | 1 | 2007 | 21 | 0.250 |
Why?
| | Adipose Tissue, White | 2 | 2019 | 43 | 0.250 |
Why?
| | Dietary Fats | 1 | 2008 | 314 | 0.240 |
Why?
| | Muscles | 3 | 2012 | 333 | 0.240 |
Why?
| | Treatment Outcome | 11 | 2026 | 11679 | 0.230 |
Why?
| | Glucagon | 1 | 2026 | 112 | 0.220 |
Why?
| | Incretins | 1 | 2025 | 21 | 0.220 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2013 | 269 | 0.210 |
Why?
| | Young Adult | 11 | 2016 | 14105 | 0.190 |
Why?
| | RNA, Messenger | 11 | 2015 | 2832 | 0.190 |
Why?
| | Adiponectin | 4 | 2009 | 244 | 0.190 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2022 | 46 | 0.190 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1158 | 0.180 |
Why?
| | Islets of Langerhans | 2 | 2005 | 833 | 0.180 |
Why?
| | Insulin, Long-Acting | 2 | 2012 | 65 | 0.180 |
Why?
| | Ligands | 3 | 2012 | 673 | 0.170 |
Why?
| | Metoclopramide | 1 | 2020 | 19 | 0.160 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5408 | 0.160 |
Why?
| | Gastric Emptying | 1 | 2020 | 36 | 0.160 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.160 |
Why?
| | Glucosides | 1 | 2020 | 55 | 0.160 |
Why?
| | Quantitative Trait Loci | 2 | 2012 | 374 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2023 | 266 | 0.160 |
Why?
| | Benzhydryl Compounds | 1 | 2020 | 82 | 0.150 |
Why?
| | China | 1 | 2020 | 269 | 0.150 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5868 | 0.150 |
Why?
| | Enteral Nutrition | 2 | 2012 | 216 | 0.150 |
Why?
| | Atherosclerosis | 2 | 2018 | 409 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2021 | 168 | 0.150 |
Why?
| | Coculture Techniques | 5 | 2011 | 246 | 0.150 |
Why?
| | Linagliptin | 1 | 2018 | 5 | 0.150 |
Why?
| | Cardiology | 1 | 2022 | 353 | 0.150 |
Why?
| | Insulin, Short-Acting | 1 | 2018 | 8 | 0.150 |
Why?
| | Cardiovascular Diseases | 3 | 2022 | 2168 | 0.140 |
Why?
| | Adipose Tissue, Brown | 1 | 2019 | 59 | 0.140 |
Why?
| | Gene Expression Profiling | 4 | 2015 | 1782 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 710 | 0.140 |
Why?
| | Quality of Life | 4 | 2025 | 3185 | 0.140 |
Why?
| | Hyperoxia | 1 | 2019 | 99 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 760 | 0.130 |
Why?
| | Comparative Effectiveness Research | 3 | 2025 | 170 | 0.130 |
Why?
| | Incidence | 2 | 2022 | 2879 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2016 | 4154 | 0.130 |
Why?
| | Stress, Psychological | 1 | 2025 | 1152 | 0.120 |
Why?
| | Overweight | 1 | 2022 | 609 | 0.120 |
Why?
| | Perioperative Care | 1 | 2018 | 231 | 0.120 |
Why?
| | Endoplasmic Reticulum | 2 | 2008 | 266 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 80 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 270 | 0.120 |
Why?
| | Abdominal Fat | 2 | 2006 | 50 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 976 | 0.110 |
Why?
| | Arginine | 2 | 2007 | 262 | 0.110 |
Why?
| | Endocrinology | 1 | 2016 | 77 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2026 | 2027 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1047 | 0.110 |
Why?
| | Cell Line | 6 | 2010 | 2882 | 0.110 |
Why?
| | Thermogenesis | 1 | 2014 | 45 | 0.110 |
Why?
| | Scavenger Receptors, Class E | 2 | 2015 | 2 | 0.110 |
Why?
| | Fish Oils | 1 | 2014 | 26 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1087 | 0.100 |
Why?
| | Area Under Curve | 1 | 2015 | 330 | 0.100 |
Why?
| | Palmitic Acid | 3 | 2011 | 42 | 0.100 |
Why?
| | Adiposity | 2 | 2010 | 543 | 0.100 |
Why?
| | Risk Factors | 7 | 2025 | 10779 | 0.100 |
Why?
| | Adolescent | 7 | 2016 | 22428 | 0.100 |
Why?
| | Hospitalization | 4 | 2018 | 2433 | 0.100 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2013 | 32 | 0.100 |
Why?
| | Medically Uninsured | 1 | 2014 | 129 | 0.100 |
Why?
| | Biopsy | 3 | 2012 | 1075 | 0.090 |
Why?
| | ROC Curve | 1 | 2015 | 614 | 0.090 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2011 | 214 | 0.090 |
Why?
| | Transcriptional Activation | 1 | 2014 | 383 | 0.090 |
Why?
| | Cardiomyopathies | 2 | 2007 | 338 | 0.090 |
Why?
| | PPAR alpha | 1 | 2012 | 54 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 635 | 0.090 |
Why?
| | CD36 Antigens | 2 | 2009 | 32 | 0.090 |
Why?
| | Cytokines | 4 | 2010 | 2061 | 0.090 |
Why?
| | Biphasic Insulins | 1 | 2011 | 3 | 0.090 |
Why?
| | Seasons | 1 | 2014 | 556 | 0.090 |
Why?
| | Insulin Lispro | 1 | 2011 | 42 | 0.090 |
Why?
| | Patient Preference | 1 | 2014 | 224 | 0.090 |
Why?
| | Hypolipidemic Agents | 2 | 2018 | 88 | 0.090 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2007 | 65 | 0.090 |
Why?
| | Temperature | 1 | 2014 | 679 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 291 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1720 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2011 | 163 | 0.080 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 83 | 0.080 |
Why?
| | Hypoglycemia | 3 | 2026 | 477 | 0.080 |
Why?
| | Collagen Type VI | 1 | 2010 | 5 | 0.080 |
Why?
| | Molecular Weight | 2 | 2008 | 327 | 0.080 |
Why?
| | Retrospective Studies | 5 | 2016 | 17066 | 0.080 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 477 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 689 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 18 | 0.080 |
Why?
| | Lipase | 1 | 2010 | 75 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2145 | 0.080 |
Why?
| | Adipogenesis | 1 | 2010 | 57 | 0.080 |
Why?
| | Body Composition | 3 | 2011 | 706 | 0.080 |
Why?
| | Lipogenesis | 1 | 2010 | 62 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4282 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 983 | 0.080 |
Why?
| | Scavenger Receptors, Class A | 1 | 2009 | 12 | 0.080 |
Why?
| | Bicycling | 1 | 2010 | 120 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 164 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 461 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2010 | 132 | 0.080 |
Why?
| | Logistic Models | 1 | 2015 | 2117 | 0.080 |
Why?
| | Myoblasts, Skeletal | 1 | 2009 | 12 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 701 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2115 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 318 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4557 | 0.070 |
Why?
| | Chemokine CCL2 | 2 | 2007 | 115 | 0.070 |
Why?
| | Heart Failure | 1 | 2022 | 2323 | 0.070 |
Why?
| | Myositis | 1 | 2009 | 57 | 0.070 |
Why?
| | Antigens, CD | 3 | 2007 | 555 | 0.070 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2009 | 158 | 0.070 |
Why?
| | Biomarkers | 4 | 2025 | 4271 | 0.070 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2008 | 66 | 0.070 |
Why?
| | Stress, Physiological | 2 | 2008 | 453 | 0.070 |
Why?
| | Thrombospondin 1 | 1 | 2007 | 28 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2011 | 474 | 0.070 |
Why?
| | Infant | 2 | 2020 | 10034 | 0.070 |
Why?
| | Retinol-Binding Proteins | 1 | 2007 | 17 | 0.070 |
Why?
| | TCF Transcription Factors | 1 | 2007 | 19 | 0.070 |
Why?
| | Extracellular Matrix | 1 | 2011 | 553 | 0.060 |
Why?
| | Adipocytes, White | 2 | 2019 | 18 | 0.060 |
Why?
| | Down-Regulation | 1 | 2009 | 627 | 0.060 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 17 | 0.060 |
Why?
| | Administration, Oral | 2 | 2020 | 847 | 0.060 |
Why?
| | Diacylglycerol O-Acyltransferase | 1 | 2006 | 5 | 0.060 |
Why?
| | Fatty Acid Synthases | 1 | 2006 | 23 | 0.060 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 56 | 0.060 |
Why?
| | Animals | 10 | 2019 | 38058 | 0.060 |
Why?
| | Liver | 3 | 2013 | 1887 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 2050 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 1045 | 0.060 |
Why?
| | Resistin | 1 | 2005 | 12 | 0.060 |
Why?
| | Glucagon-Secreting Cells | 1 | 2026 | 26 | 0.060 |
Why?
| | Niacin | 1 | 2005 | 16 | 0.060 |
Why?
| | Insulins | 1 | 2026 | 38 | 0.060 |
Why?
| | Child, Preschool | 1 | 2020 | 11787 | 0.060 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 1406 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2025 | 41 | 0.060 |
Why?
| | Fructosamine | 1 | 2004 | 11 | 0.050 |
Why?
| | Quality Improvement | 1 | 2014 | 1289 | 0.050 |
Why?
| | Walk Test | 1 | 2025 | 80 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 612 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2005 | 327 | 0.050 |
Why?
| | Apolipoproteins E | 1 | 2004 | 94 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2363 | 0.050 |
Why?
| | Veterans | 1 | 2016 | 1603 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2024 | 47 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2006 | 222 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2026 | 779 | 0.050 |
Why?
| | Models, Biological | 2 | 2008 | 1821 | 0.050 |
Why?
| | Leptin | 1 | 2005 | 245 | 0.050 |
Why?
| | Phenotype | 1 | 2012 | 3162 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 459 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2026 | 675 | 0.050 |
Why?
| | Elastin | 2 | 2014 | 79 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3890 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2025 | 283 | 0.050 |
Why?
| | Anti-Obesity Agents | 2 | 2018 | 64 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2006 | 281 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 88 | 0.040 |
Why?
| | Apoptosis | 2 | 2011 | 2430 | 0.040 |
Why?
| | Arteriosclerosis | 1 | 2002 | 84 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2004 | 210 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2006 | 748 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 288 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 114 | 0.040 |
Why?
| | American Heart Association | 1 | 2022 | 350 | 0.040 |
Why?
| | Child | 1 | 2020 | 22633 | 0.040 |
Why?
| | Recovery of Function | 1 | 2025 | 707 | 0.040 |
Why?
| | Albuminuria | 1 | 2021 | 190 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2007 | 741 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 221 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 209 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 405 | 0.040 |
Why?
| | Calibration | 1 | 2020 | 151 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 212 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1217 | 0.040 |
Why?
| | Creatinine | 1 | 2021 | 506 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2112 | 0.040 |
Why?
| | Adipocytes, Brown | 1 | 2019 | 8 | 0.040 |
Why?
| | Health Status Indicators | 1 | 2020 | 166 | 0.040 |
Why?
| | Streptozocin | 1 | 2019 | 21 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2006 | 1339 | 0.040 |
Why?
| | Carbohydrate Metabolism | 1 | 2019 | 60 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2018 | 64 | 0.040 |
Why?
| | Mice | 7 | 2013 | 18339 | 0.030 |
Why?
| | Transcription Factors | 2 | 2008 | 1741 | 0.030 |
Why?
| | Fasting | 1 | 2020 | 277 | 0.030 |
Why?
| | Treatment Failure | 1 | 2019 | 365 | 0.030 |
Why?
| | Digestive System Surgical Procedures | 1 | 2018 | 109 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2019 | 451 | 0.030 |
Why?
| | Urologic Surgical Procedures | 1 | 2018 | 115 | 0.030 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 198 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 769 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 261 | 0.030 |
Why?
| | Transfection | 2 | 2010 | 940 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 965 | 0.030 |
Why?
| | Blotting, Western | 2 | 2010 | 1187 | 0.030 |
Why?
| | Reference Values | 2 | 2008 | 797 | 0.030 |
Why?
| | G(M2) Activator Protein | 1 | 2015 | 1 | 0.030 |
Why?
| | Myosin Type V | 1 | 2015 | 9 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 243 | 0.030 |
Why?
| | Registries | 1 | 2025 | 2385 | 0.030 |
Why?
| | ADAM Proteins | 1 | 2015 | 63 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1558 | 0.030 |
Why?
| | 3T3 Cells | 2 | 2006 | 156 | 0.030 |
Why?
| | Uncoupling Protein 1 | 1 | 2014 | 17 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8265 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 185 | 0.030 |
Why?
| | Fibroblasts | 2 | 2011 | 1034 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 521 | 0.030 |
Why?
| | Ion Channels | 1 | 2014 | 129 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 836 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 510 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 758 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 7173 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2013 | 3121 | 0.020 |
Why?
| | Genome, Human | 1 | 2015 | 422 | 0.020 |
Why?
| | Mast Cells | 1 | 2014 | 146 | 0.020 |
Why?
| | Hypertension | 1 | 2021 | 1263 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 262 | 0.020 |
Why?
| | Demography | 1 | 2013 | 288 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 592 | 0.020 |
Why?
| | Organ Specificity | 1 | 2012 | 312 | 0.020 |
Why?
| | TWEAK Receptor | 1 | 2011 | 6 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 851 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 49 | 0.020 |
Why?
| | Tripartite Motif Proteins | 1 | 2011 | 40 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 372 | 0.020 |
Why?
| | 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2010 | 3 | 0.020 |
Why?
| | Atrophy | 1 | 2011 | 201 | 0.020 |
Why?
| | United States | 2 | 2022 | 15966 | 0.020 |
Why?
| | Receptors, Adiponectin | 1 | 2010 | 22 | 0.020 |
Why?
| | Capillaries | 1 | 2011 | 124 | 0.020 |
Why?
| | Acyltransferases | 1 | 2010 | 78 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5597 | 0.020 |
Why?
| | Protein Kinase C-alpha | 1 | 2010 | 37 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 192 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 370 | 0.020 |
Why?
| | Muscle Proteins | 1 | 2011 | 244 | 0.020 |
Why?
| | Stromal Cells | 1 | 2010 | 124 | 0.020 |
Why?
| | Th1 Cells | 1 | 2010 | 139 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2010 | 151 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 456 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2008 | 37 | 0.020 |
Why?
| | Regulatory Factor X Transcription Factors | 1 | 2008 | 11 | 0.020 |
Why?
| | Mice, Obese | 1 | 2008 | 66 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 2008 | 40 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 935 | 0.020 |
Why?
| | Activating Transcription Factor 6 | 1 | 2008 | 21 | 0.020 |
Why?
| | X-Box Binding Protein 1 | 1 | 2008 | 16 | 0.020 |
Why?
| | eIF-2 Kinase | 1 | 2008 | 29 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2008 | 32 | 0.020 |
Why?
| | Patient Readmission | 1 | 2014 | 758 | 0.020 |
Why?
| | Chelating Agents | 1 | 2008 | 71 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1886 | 0.020 |
Why?
| | Sucrose | 1 | 2008 | 112 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2008 | 80 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2007 | 6 | 0.020 |
Why?
| | Cell Fractionation | 1 | 2007 | 52 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2008 | 138 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2010 | 724 | 0.020 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2007 | 26 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2007 | 38 | 0.020 |
Why?
| | Patient Discharge | 1 | 2014 | 983 | 0.020 |
Why?
| | Indians, North American | 1 | 2013 | 647 | 0.020 |
Why?
| | Cell Communication | 1 | 2009 | 324 | 0.020 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2006 | 8 | 0.020 |
Why?
| | Phosphatidate Phosphatase | 1 | 2006 | 4 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2006 | 204 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 402 | 0.020 |
Why?
| | Muscle Cells | 1 | 2006 | 42 | 0.020 |
Why?
| | Signal Transduction | 2 | 2011 | 5226 | 0.020 |
Why?
| | Isomerism | 1 | 2006 | 57 | 0.020 |
Why?
| | Caspase 9 | 1 | 2006 | 55 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2008 | 200 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 121 | 0.020 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2006 | 37 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2008 | 344 | 0.010 |
Why?
| | Anilides | 1 | 2006 | 84 | 0.010 |
Why?
| | DNA Primers | 1 | 2006 | 512 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 238 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2006 | 5992 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 232 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2947 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 375 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 320 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1047 | 0.010 |
Why?
| | Genome | 1 | 2006 | 306 | 0.010 |
Why?
| | Life Style | 1 | 2006 | 479 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2004 | 275 | 0.010 |
Why?
| | Colorado | 1 | 2014 | 4564 | 0.010 |
Why?
| | RNA | 1 | 2010 | 940 | 0.010 |
Why?
| | Homeostasis | 1 | 2007 | 640 | 0.010 |
Why?
| | Stem Cells | 1 | 2007 | 626 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2004 | 192 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2190 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 621 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2006 | 699 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2155 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1833 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2930 | 0.010 |
Why?
| | Antioxidants | 1 | 2006 | 549 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1716 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1183 | 0.010 |
Why?
| | Myocardium | 1 | 2006 | 939 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2002 | 153 | 0.010 |
Why?
| | Morbidity | 1 | 2002 | 323 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 1499 | 0.010 |
Why?
| | Cardiovascular System | 1 | 2002 | 137 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2002 | 268 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1257 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7990 | 0.010 |
Why?
| | Mortality | 1 | 2002 | 375 | 0.010 |
Why?
| | Mitochondria | 1 | 2006 | 984 | 0.010 |
Why?
|
|
Rasouli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|